Positions

Overview

  • Dr. Cooper is a board-certified internist and pulmonologist. He currently sits on the board for Pulmonary Diseases of ABIM. He is Professor of Medicine at the University of Alabama Medical School and Chief of the Pulmonary Section at the Birmingham Veterans Administration Medical Center. He was Director for the University of Alabama Pulmonary and Critical Care Fellowship Training Program for 15 years and has received multiple teaching awards from the university.

    Currently, Dr. Cooper serves on two Institutional Review Boards, one at the Birmingham VAMC and the for the entire Veterans Affairs human research program (VA Central IRB). He has been involved in basic and clinical research through his entire career. He has received research funding through NIH and VA as well as other organizations.

    Dr. Cooper earned his medical degree at Duke University, completed a medical internship at the University of Washington and residency at the University of Virginia. He completed fellowship training in Pulmonary and Critical Care Medicine at Yale University prior to joining the faculty there, before moving to the University of Alabama at Birmingham.

    He currently is funded through the NIH for clinical research in patients with chronic obstructive pulmonary disease (COPD).

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Serum IgG Levels and Risk of COPD Hospitalization: A Pooled Meta-analysis..  Chest.  2020
    2020 Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial..  Chest.  2020
    2019 Metoprolol for the prevention of acute exacerbations of COPD.  New England Journal of Medicine.  381:2304-2314. 2019
    2018 Clinical differences in COPD patients with variable patterns of hypoxemia.  Chronic obstructive pulmonary diseases (Miami, Fla.).  5:167-178. 2018
    2018 The long-term oxygen treatment trial for chronic obstructive pulmonary disease: Rationale, design, and lessons learned.  Annals of the American Thoracic Society.  15:89-101. 2018
    2017 Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD).  Respiratory Research.  18. 2017
    2016 A randomized trial of long-term oxygen for COPD with moderate desaturation.  New England Journal of Medicine.  375:1617-1627. 2016
    2014 Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.  New England Journal of Medicine.  370:2201-2210. 2014
    2012 Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.  Clinical Infectious Diseases.  55. 2012
    2012 Influence of lightweight ambulatory oxygen on oxygen use and activity patterns of COPD patients receiving long-term oxygen therapy.  COPD: Journal of Chronic Obstructive Pulmonary Disease.  9:3-11. 2012
    2011 Azithromycin for prevention of exacerbations of COPD.  New England Journal of Medicine.  365:689-698. 2011
    2011 Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization.  COPD: Journal of Chronic Obstructive Pulmonary Disease.  8:21-29. 2011
    2009 Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting. 2009
    2005 Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: A randomized trial.  Annals of Internal Medicine.  143. 2005
    2004 Infiltrative lung disease due to noncytotoxic agents.  Clinics in Chest Medicine.  25:47-52. 2004
    2001 Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis.  American Journal of Respiratory and Critical Care Medicine.  164:193-196. 2001
    2001 Attenuation of interleukin 8-induced nasal inflammation by an inhibitor peptide.  American Journal of Respiratory and Critical Care Medicine.  163:1198-1205. 2001
    2000 Attenuation of interleukin-8 production by inhibiting nuclear factor-κB translocation using decoy oligonucleotides.  Biochemical Pharmacology.  59:605-613. 2000
    2000 Pulmonary fibrosis. Pathways are slowly coming into light.  American Journal of Respiratory Cell and Molecular Biology.  22:520-523. 2000
    1999 Modulation of monocyte chemokine production and nuclear factor kappa B activity by oxidants.  Journal of Interferon and Cytokine Research.  19:761-767. 1999
    1999 Pulmonary malacoplakia associated with Rhodococcus equi infection in a patient with AIDS..  Chest.  115:889-892. 1999
    1998 Modulation of monocyte chemotactic protein-1 production by hyperoxia: Importance of RNA stability in control of cytokine production.  American Journal of Respiratory Cell and Molecular Biology.  18:521-525. 1998
    1996 Attenuation of NFKB binding activity using oligonucleotides as decoys.  Journal of Investigative Medicine.  44. 1996
    1996 Characterization of a Neutrophil Inhibitor Peptide Harvested from Human Bronchial Lavage: Homology to Influenza A Nucleoprotein.  American Journal of Respiratory Cell and Molecular Biology.  15:207-215. 1996
    1996 Effects of hyperoxia on MCP RNA stability.  Journal of Investigative Medicine.  44. 1996
    1996 Effects of influenza A nucleoprotein on polymorphonuclear neutrophil function.  Journal of Infectious Diseases.  173:279-284. 1996
    1994 Hyperoxia stimulates interleukin-8 release from alveolar macrophages and U937 cells: attenuation by dexamethasone..  American Journal of Physiology.  267:L187-L192. 1994
    1994 Alteration of cellular cytosolic calcium and chemotactic peptide binding by an inhibitor of neutrophil function..  American Journal of Physiology.  267:L71-L78. 1994
    1994 Alteration of cellular cytosolic calcium and chemotactic peptide binding by an inhibitor of neutrophil function 1994
    1994 Hyperoxia stimulates interleukin-8 release from alveolar macrophages and U937 cells: Attenuation by dexamethasone 1994
    1994 Mediation of lung neutrophil uptake after endotoxin by CD18-integrin- dependent and -independent mechanisms.  American Journal of Physiology.  266. 1994
    1993 Radiation pneumonitis: Bronchoalveolar lavage assessment and modulation by a recombinant cytokine.  The American review of respiratory disease.  148:1671-1676. 1993
    1992 Effects of in vitro amiodarone exposure on alveolar macrophage inflammatory mediator production.  American Journal of the Medical Sciences.  304:352-356. 1992
    1991 Isolation of an inhibitor of neutrophil function from bronchial lavage of normal volunteers..  American Journal of Physiology.  260:L501-L509. 1991
    1991 Isolation of an inhibitor of neutrophil function from bronchial lavage of normal volunteers.  American Journal of Physiology.  260. 1991
    1990 Preface.  Clinics in Chest Medicine.  11. 1990
    1990 Pulmonary disease due to antirheumatic agents.  Clinics in Chest Medicine.  11:139-150. 1990
    1989 Human alveolar macrophages release a factor that inhibits phagocyte function..  American Journal of Respiratory Cell and Molecular Biology.  1:407-416. 1989
    1989 Kinetics of cellular influx and histamine release in normal human bronchi.  American Journal of Physiology.  257. 1989
    1989 Modulation of endoperoxide product levels and cyclophosphamide-induced injury by glutathione repletion 1989
    1988 Bronchoalveolar cell activation after inhalation of a bronchoconstricting agent 1988
    1987 Drug-induced pulmonary disease.  Disease-A-Month.  33:66-120. 1987
    1987 Relationship of the ventilatory response to cotton bract extract and the cells and proteins of the lung.  Chest.  91:44-48. 1987
    1986 Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism. Possible mechanisms of pulmonary pharmacotoxicity.  The American review of respiratory disease.  134:108-114. 1986
    1986 Drug-induced pulmonary disease. Part 1: Cytotoxic drugs.  The American review of respiratory disease.  133:321-340. 1986
    1986 Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs.  The American review of respiratory disease.  133:488-505. 1986
    1986 The relationship between bronchoalveolar neutrophil recruitment and bronchoconstriction induced by a soluble extract of cotton bracts.  The American review of respiratory disease.  134:975-982. 1986
    1986 Vegetable dust and airway disease: Inflammatory mechanisms.  Environmental Health Perspectives.  VOL. 66:7-15. 1986
    1985 Acute bilobar collapse secondary to endobronchial metastatic seminoma.  Canadian Association of Radiologists Journal.  36:166-167. 1985
    1984 Effects of a series of chloromethyl ketone protease inhibitors on superoxide release and the glutathione system in human polymorphonuclear leukocytes and alveolar macrophages.  The American review of respiratory disease.  130:110-114. 1984
    1984 Hermansky-Pudlak syndrome and interstitial lung disease: Report of a case with lavage findings.  The American review of respiratory disease.  130:138-141. 1984

    Book

    Year Title Altmetric
    1988 Mechanisms of drug-induced pulmonary disease.  Ed. 39.  1988

    Chapter

    Year Title Altmetric
    2010 Pneumonitis induced by non-cytotoxic agents.  229-239. 2010

    Research Overview

  • Dr. Cooper was initially involved with basic science research when he came to UAB. This research focused on control of acute lung inflammation. He subsequently has transitioned to clinical research focused on treatment of patients with COPD. He is principal investigator for the Long term Oxygen Treatment Trial (LOTT) funded through the NIH and is co-PI on the NIH funded COPD Clinical Research Network. He is also Local Site Investigator examining efficacy of corticosteroids in severe community acquired pneumonia funded by the VA Cooperative Studies Program. He is PI currently and in the past on numerous industry-funded clinical trials as well.

    • Principal Investigator On

    Investigator On

    Education And Training

  • University of Washington Affiliated Hospitals, Internship
  • University of Virginia Medical Center, Residency
  • Yale - New Haven Hospital, Postdoctoral Fellowship
  • University of Washington Medical Center, Internship 1979
  • University of Virginia Hospital, Residency 1981

    • Full Name

  • J. Allen Cooper